{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"19.6","value":"13.7"},{"comment":"Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.","groupId":"OG001","lowerLimit":"8.5","upperLimit":"NA","value":"14.1"},{"comment":"Median and 95% confidence interval were not calculable due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"2.7","upperLimit":"NA","value":"NA"},{"comment":"Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.","groupId":"OG003","lowerLimit":"5.0","upperLimit":"NA","value":"11.1"},{"groupId":"OG004","lowerLimit":"2.6","upperLimit":"8.6","value":"4.3"},{"groupId":"OG005","lowerLimit":"4.2","upperLimit":"11.0","value":"8.2"},{"groupId":"OG006","lowerLimit":"7.2","upperLimit":"14.3","value":"11.3"},{"groupId":"OG007","lowerLimit":"2.7","upperLimit":"5.6","value":"4.0"},{"comment":"Missing upper bound is related to right-censored data. Last time point censored and estimate is essentially infinity, therefore it is NA.","groupId":"OG008","lowerLimit":"2.8","upperLimit":"NA","value":"11.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"23"}],"units":"Participants"}],"description":"Progression-free survival (PFS) by independent central review was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG000","title":"Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg"},{"description":"Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG001","title":"Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg"},{"description":"Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG002","title":"Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg"},{"description":"Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG003","title":"Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg"},{"description":"Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG004","title":"Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg"},{"description":"Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG005","title":"Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg"},{"description":"Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG006","title":"Dose Expansion: HER2-expressing NSCLC Tumors"},{"description":"Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG007","title":"Dose Expansion: HER2-expressing Colorectal Tumors"},{"description":"Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG008","title":"Dose Expansion: HER2-expressing Other Solid Tumors"}],"paramType":"MEDIAN","populationDescription":"PFS was assessed in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"From 6 months postdose of last participant up to 3 years 5 months","title":"Progression-free Survival Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)","type":"SECONDARY","unitOfMeasure":"months"}